Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Vínculo: A Digital Intervention for Anxiety, Depression, and Insomnia Symptoms (VINCULO-ADI)

15 de novembro de 2026 atualizado por: Renatha El Rafihi-Ferreira, University of Sao Paulo

Vínculo: A Randomized Controlled Trial of a Guided Digital Intervention for Anxiety, Depression, and Insomnia Symptoms

Insomnia, anxiety, and depression are common mental health problems that frequently occur together. Psychological interventions that address shared processes underlying these symptoms may offer an accessible way to improve mental health and sleep.

This study will evaluate the effectiveness of Vínculo, an eight-week, guided digital psychological intervention for adults experiencing clinically significant symptoms of insomnia, anxiety, and/or depression.

Approximately 305 adults living in Brazil will be randomly assigned to one of two groups. The experimental group will receive Vínculo, a psychological intervention delivered through a WhatsApp chatbot that combines acceptance and commitment therapy, behavioral activation, and behavioral strategies for sleep. The comparison group will receive an eight-week digital psychoeducation program covering mental health, emotions, sleep, and healthy lifestyle habits.

Both groups will receive structured content through WhatsApp, three individual videoconference sessions with a psychologist, and access to asynchronous psychological support during the intervention.

The main objective is to determine whether Vínculo is more effective than digital psychoeducation in reducing insomnia severity, depressive symptoms, and anxiety symptoms after eight weeks. Participants will also be assessed three and six months after the intervention to examine whether improvements are maintained. Additional assessments will examine daily functioning and psychological processes related to treatment outcomes.

Visão geral do estudo

Status

Ainda não está recrutando

Condições

Intervenção / Tratamento

Descrição detalhada

This study is a fully remote, open-label, two-arm, parallel-group randomized controlled trial designed to evaluate the efficacy of Vínculo, a guided digital transdiagnostic psychological intervention, compared with an active digital psychoeducation control condition.

The study will enroll approximately 305 adults aged 18-59 years living in Brazil who report clinically significant symptoms in at least one of three domains: insomnia, depression, or anxiety. Eligibility will be established through electronic screening followed by a structured clinical assessment. A formal psychiatric diagnosis will not be required for inclusion.

After baseline assessment, participants will be randomized in a 1:1 ratio using computer-generated, randomly permuted blocks of varying sizes. Randomization will be stratified according to eight possible baseline symptom profiles, defined by the presence or absence of clinically significant insomnia, depression, and anxiety symptoms. Allocation will be implemented through REDCap.

The experimental intervention is based on process-based therapy and integrates components of acceptance and commitment therapy, behavioral activation, and behavioral strategies for insomnia. Therapeutic content will address emotional awareness, experiential avoidance, mindfulness, values clarification, committed action, behavioral activation, acceptance, cognitive defusion, sleep-related behaviors, and relapse prevention. Behavioral sleep strategies will be introduced in Week 4 and will not include sleep restriction.

The active control condition will provide structured psychoeducation about mental health, emotional symptoms, sleep, and healthy lifestyle habits without introducing the specific therapeutic techniques of the experimental intervention.

Both conditions will last eight weeks. Structured digital content will be delivered through WhatsApp three times weekly, with reminders on alternate days. Participants in both groups will receive three individual videoconference sessions with a psychologist and access to asynchronous professional support on business days. The content of professional support will be specific to each assigned condition.

The three co-primary outcomes are insomnia severity, depressive symptoms, and anxiety symptoms, assessed one week after completion of the eight-week intervention using the Insomnia Severity Index (ISI), Patient Health Questionnaire-9 (PHQ-9), and Generalized Anxiety Disorder-7 (GAD-7), respectively.

Secondary assessments will examine symptom severity at three- and six-month follow-ups, functional impairment, clinical response, behavioral activation, and psychological flexibility. Exploratory assessments will address anhedonia and working alliance.

The primary analyses will compare treatment groups while accounting for baseline symptom severity. The study will also investigate treatment effects across different baseline symptom presentations and evaluate changes in psychological processes associated with clinical outcomes.

Tipo de estudo

Intervencional

Inscrição (Estimado)

305

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • São Paulo
      • São Paulo, São Paulo, Brasil, 05508-030
        • Institute of Psychology, University of São Paulo
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 59 anos (Adulto)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Adults aged 18 to 59 years.
  • Clinically significant symptoms in at least one of the following domains at screening:
  • Insomnia: Insomnia Severity Index (ISI) score ≥11;
  • Depression: Patient Health Questionnaire-9 (PHQ-9) score ≥10;
  • Anxiety: Generalized Anxiety Disorder-7 (GAD-7) score ≥10.
  • Residence in Brazil.
  • Ability to read and understand written Portuguese.
  • Regular access to WhatsApp on a personal device.
  • Willingness and availability to participate in the intervention and complete the scheduled study assessments.
  • Provision of electronic informed consent.

Exclusion Criteria:

  • Current diagnosis of bipolar disorder or psychotic disorder, or severe suicide risk.
  • Substance use disorder that would substantially interfere with participation in the intervention or completion of study assessments.
  • Severe and unstable neurological or medical conditions, such as dementia or advanced-stage cancer.
  • Night-shift work that cannot be reorganized.
  • Significant cognitive impairment that would hinder participation in the digital intervention.
  • Unavailability to participate in the intervention or complete the scheduled study assessments.
  • Use of sleep medication, either regularly or intermittently, without a stable medication use pattern for at least 2 months before enrollment, including recent initiation or substantial changes in the regimen.
  • Use of antidepressants or other psychotropic medications intended for regular use without a stable regimen for at least 1 month following a dose adjustment or 2 months following initiation of a new medication.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Vínculo Digital Intervention

Participants will receive Vínculo, an eight-week guided digital transdiagnostic psychological intervention delivered through a WhatsApp chatbot. The intervention integrates acceptance and commitment therapy, behavioral activation, and behavioral sleep strategies. Structured content will be delivered on Mondays, Wednesdays, and Fridays, with reminders on Tuesdays, Thursdays, and Saturdays. Participants will also receive three individual videoconference sessions with a psychologist (before treatment, Week 4, and Week 8) and asynchronous psychological support on business days (Monday to Friday).

Vínculo is an eight-week guided digital transdiagnostic psychological intervention delivered through a WhatsApp chatbot. Based on process-based therapy, it integrates acceptance and commitment therapy, behavioral activation, and behavioral sleep regulation. Components include mindfulness, acceptance, cognitive defusion, values clarification, committed action, and behavioral activation. Sleep-related content is addressed throughout the intervention, including psychoeducation, stimulus control, a consistent wake time, daytime activity, morning natural light exposure, and a wind-down routine. Content is delivered three times weekly, with reminders on alternate days. Participants receive three individual videoconference sessions with a psychologist (before treatment, Week 4, and Week 8) and asynchronous psychological support on business days.

Comparador Ativo: Digital Psychoeducation

Participants will receive an eight-week digital psychoeducation program delivered through a WhatsApp chatbot. The program provides information about mental health, emotional symptoms, sleep, and healthy lifestyle habits, without introducing the specific therapeutic techniques used in the experimental intervention. Structured content will be delivered on Mondays, Wednesdays, and Fridays, with reminders on Tuesdays, Thursdays, and Saturdays. Participants will also receive three individual videoconference sessions with a psychologist (before treatment, Week 4, and Week 8) and asynchronous professional support on business days (Monday to Friday), limited to clarifying psychoeducational content, addressing technical difficulties, and supporting engagement.

An eight-week digital psychoeducation program delivered through a WhatsApp chatbot. The program provides structured information about mental health, emotional symptoms, sleep, and healthy lifestyle habits, without introducing the specific therapeutic techniques of the experimental intervention. Content is delivered three times weekly, with reminders on alternate days. Participants receive three individual videoconference sessions with a psychologist (before treatment, Week 4, and Week 8) and asynchronous professional support on business days. Professional support is limited to clarifying psychoeducational content, addressing technical difficulties, and supporting engagement.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Insomnia Symptom Severity (Insomnia Severity Index - ISI)
Prazo: One week after completion of the 8-week intervention

The Insomnia Severity Index (ISI) is a seven-item self-report questionnaire assessing insomnia symptom severity. Total scores range from 0 to 28, with higher scores indicating greater insomnia severity. The primary outcome is the ISI total score at post-treatment, adjusted for baseline severity.

One week after completion of the 8-week intervention
Depressive Symptom Severity (Patient Health Questionnaire-9 - PHQ-9)
Prazo: One week after completion of the 8-week intervention

The Patient Health Questionnaire-9 (PHQ-9) is a nine-item self-report questionnaire assessing depressive symptom severity. Total scores range from 0 to 27, with higher scores indicating greater depressive symptom severity. The primary outcome is the PHQ-9 total score at post-treatment, adjusted for baseline severity.

One week after completion of the 8-week intervention
Anxiety Symptom Severity (Generalized Anxiety Disorder-7 - GAD-7)
Prazo: One week after completion of the 8-week intervention

The Generalized Anxiety Disorder-7 (GAD-7) is a seven-item self-report questionnaire assessing anxiety symptom severity. Total scores range from 0 to 21, with higher scores indicating greater anxiety severity. The primary outcome is the GAD-7 total score at post-treatment, adjusted for baseline severity.

One week after completion of the 8-week intervention

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Insomnia Symptom Severity at Follow-up (Insomnia Severity Index - ISI)
Prazo: 3 and 6 months after completion of the 8-week intervention

The Insomnia Severity Index (ISI) is a seven-item self-report questionnaire assessing insomnia symptom severity. Total scores range from 0 to 28, with higher scores indicating greater insomnia severity. ISI total scores will be assessed at the 3-month and 6-month follow-ups to evaluate maintenance of treatment effects, adjusting for baseline severity.

3 and 6 months after completion of the 8-week intervention
Depressive Symptom Severity at Follow-up (Patient Health Questionnaire-9 - PHQ-9)
Prazo: 3 and 6 months after completion of the 8-week intervention

The Patient Health Questionnaire-9 (PHQ-9) is a nine-item self-report questionnaire assessing depressive symptom severity. Total scores range from 0 to 27, with higher scores indicating greater depressive symptom severity. PHQ-9 total scores will be assessed at the 3-month and 6-month follow-ups to evaluate maintenance of treatment effects, adjusting for baseline severity.

3 and 6 months after completion of the 8-week intervention
Anxiety Symptom Severity at Follow-up (Generalized Anxiety Disorder-7 - GAD-7)
Prazo: 3 and 6 months after completion of the 8-week intervention

The Generalized Anxiety Disorder-7 (GAD-7) is a seven-item self-report questionnaire assessing anxiety symptom severity. Total scores range from 0 to 21, with higher scores indicating greater anxiety severity. GAD-7 total scores will be assessed at the 3-month and 6-month follow-ups to evaluate maintenance of treatment effects, adjusting for baseline severity.

3 and 6 months after completion of the 8-week intervention
Functional Impairment (Sheehan Disability Scale - SDS)
Prazo: One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups

The Sheehan Disability Scale (SDS) is a three-item self-report measure assessing functional impairment in work or school, social life, and family life or home responsibilities. Each domain is scored from 0 to 10, with a total score ranging from 0 to 30. Higher scores indicate greater functional impairment.

One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
Behavioral Activation (Behavioral Activation for Depression Scale - Short Form, BADS-SF)
Prazo: Week 4, one week after completion of the 8-week intervention, and at 3- and 6-month follow-ups

The Behavioral Activation for Depression Scale - Short Form (BADS-SF) is a nine-item self-report measure assessing behavioral activation and avoidance. Total scores range from 0 to 54, with higher scores indicating greater behavioral activation. Changes in behavioral activation will be evaluated across the scheduled assessments.

Week 4, one week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
Psychological Flexibility (Comprehensive Assessment of Acceptance and Commitment Therapy Processes - CompACT)
Prazo: Week 4, one week after completion of the 8-week intervention, and at 3- and 6-month follow-ups

The Comprehensive Assessment of Acceptance and Commitment Therapy Processes (CompACT) is a 23-item self-report measure assessing psychological flexibility through openness to experience, behavioral awareness, and valued action. Total scores range from 0 to 138, with higher scores indicating greater psychological flexibility.

Week 4, one week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
Clinical Response in Insomnia Symptoms (ISI)
Prazo: One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups

Clinical response in insomnia symptoms will be defined as a reduction of at least 8 points in the Insomnia Severity Index (ISI) total score relative to baseline. The outcome will be expressed as the proportion of participants meeting this predefined response criterion at each assessment.

One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
Clinical Response in Depressive Symptoms (PHQ-9)
Prazo: One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups

Clinical response in depressive symptoms will be defined as a reduction of at least 50% in the Patient Health Questionnaire-9 (PHQ-9) total score relative to baseline. The outcome will be expressed as the proportion of participants meeting this predefined response criterion at each assessment.

One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
Clinical Response in Anxiety Symptoms (GAD-7)
Prazo: One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups

Clinical response in anxiety symptoms will be defined as a reduction of at least 50% in the Generalized Anxiety Disorder-7 (GAD-7) total score relative to baseline. The outcome will be expressed as the proportion of participants meeting this predefined response criterion at each assessment.

One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Anhedonia (Snaith-Hamilton Pleasure Scale - SHAPS)
Prazo: One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups

The Snaith-Hamilton Pleasure Scale (SHAPS) is a 14-item self-report questionnaire assessing anhedonia, defined as a reduced capacity to experience pleasure. Using conventional dichotomous scoring, total scores range from 0 to 14, with higher scores indicating greater anhedonia. Changes in anhedonia will be evaluated as an exploratory outcome.

One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
Therapeutic Alliance (Working Alliance Inventory for Guided Internet Interventions - WAI-I)
Prazo: Week 4 and one week after completion of the 8-week intervention

The Working Alliance Inventory for Guided Internet Interventions (WAI-I) is a self-report measure assessing the therapeutic alliance in guided internet-based psychological interventions, including agreement on therapeutic goals, agreement on tasks, and the therapeutic bond. Higher scores indicate a stronger therapeutic alliance. Therapeutic alliance will be evaluated as an exploratory outcome.

Week 4 and one week after completion of the 8-week intervention

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Renatha El Rafihi-Ferreira, PhD, University of Sao Paulo

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de maio de 2027

Conclusão Primária (Estimado)

1 de julho de 2029

Conclusão do estudo (Estimado)

1 de novembro de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

15 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

15 de novembro de 2026

Primeira postagem (Real)

20 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

20 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

15 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • CISM-VINCULO-ADI

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Descrição do plano IPD

Individual participant data sharing has not yet been determined. Study data will be securely stored, and access will be restricted to authorized research personnel in accordance with institutional policies, ethical approvals, and Brazilian data protection legislation. The possibility of sharing de-identified participant data for scientific purposes will be evaluated in accordance with applicable ethical and institutional requirements.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .